Table 9.5Summary of economic evaluations of ARB to treat CKD

Study and countryARBAuthorsTime horizon (years)Discount rate (% p.a.)
CostsEffects
IDNT (diabetes)Irbesartan
UK2581061.5
US2593, 10 and 2533
Switzerland2602555
Canadian2612533
Belgium and France258Lifetime33
RENAAL (diabetes)Losartan
UK262Lifetime3.53.5
US2633.53.5NM
Switzerland2643.5NMNM
Canadian2654NMNM
France2665NMNM

NM = not modelled.

From: 9, Blood pressure control

Cover of Chronic Kidney Disease
Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care.
NICE Clinical Guidelines, No. 73.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.